Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy Combined With Anlotinib in LA-NSCLC Intolerable to cCRT
NCT07037680Phase 2Completed
- Start
- Jan 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in non-small cell lung cancer (NSCLC). Started Jan 2024; status: completed.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07037680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07037680.